Nano-Therapeutics in Diabetes Mellitus: Revolutionizing Diagnosis, Treatment, and Drug Delivery

Year : 2025 | Volume : 12 | Issue : 02 | Page : 08 19
    By

    Sujeet Kumar Thakur,

  • Kamalesh Mistry,

  • Dhananjay Mistry,

  1. Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  2. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  3. Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India

Abstract

Diabetes mellitus is a chronic metabolic disorder in which blood glucose concentration remains high over an extended duration, resulting in significant lethal complications, including neuropathy, nephropathy and cardiovascular diseases. However, conventional diabetes management strategies, including insulin therapy and oral hypoglycemic agents, rarely exhibit poor bioavailability, high doses, off target delivery, etc. Nanotechnology has brought the rise of diabetes treatment revolution, by overcoming the challenges present in standard treatment, owing to the emergence of nanotechnology, which has allowed precise drug delivery, real time glucose monitoring and regenerative therapy. In this review, nanotechnology roles in diabetes are discussed with regards to two of its three dimensions; specifically, the existing nano-based therapeutics, drug delivery systems and biosensing technologies in the management of diabetic condition. The recent advances in the polymeric nanoparticles, liposomes, micelles, hydrogels and metallic nanoparticles have greatly enhanced insulin delivery, non-insulin drug delivery, and glucose monitoring. Furthermore, artificial intelligence hybridized nanomedicine is personalized diabetes management by improving treatment strategies and predictive analytics. To thoroughly review recent trends in nano-therapeutics for diabetes, extensive literature review on Scopus and SCI indexed journals was performed for the identification of certain parameters, like bioavailability, drug release kinetics, biocompatibility and therapeutic efficacy. Controlled and targeted drug delivery is one of the powerful features utilized by nanotechnology to better treat diabetes. Improved insulin stability and prolonged systemic circulation of polymeric nanoparticles and lipid based nanocarriers, real time glucose monitoring using glucose responsive nanocarriers and biosensors have reduced risks of hypo and hyperglycemia. With respect to the application of regenerative nanomedicine, such as stem cell loaded nanoparticles and gene therapy, regenerative nanomedicine has emerged as a new direction for pancreatic beta cell regeneration and as a potential curative treatment for diabetes. However, there are many challenges to patient use, such as large-scale manufacture, regulatory approvals and long-term safety issues that need to be overcome before clinical translation. The future research should concentrate on designing hybrid nanoplatforms, biodegradable nanocarriers and AI integrated nano diagnostics to improve personalized diabetes care.

Keywords: Diabetes Mellitus, Nanotechnology, Nano-Therapeutics, Insulin Nanocarriers, Biosensors, Personalized Medicine, Artificial Intelligence

[This article belongs to Trends in Drug Delivery ]

How to cite this article:
Sujeet Kumar Thakur, Kamalesh Mistry, Dhananjay Mistry. Nano-Therapeutics in Diabetes Mellitus: Revolutionizing Diagnosis, Treatment, and Drug Delivery. Trends in Drug Delivery. 2025; 12(02):08-19.
How to cite this URL:
Sujeet Kumar Thakur, Kamalesh Mistry, Dhananjay Mistry. Nano-Therapeutics in Diabetes Mellitus: Revolutionizing Diagnosis, Treatment, and Drug Delivery. Trends in Drug Delivery. 2025; 12(02):08-19. Available from: https://journals.stmjournals.com/tdd/article=2025/view=216470


References

  1. Bhatt MP, Dhamoon AS. Nanomedicine approaches in diabetes therapy: Challenges and prospects. J Diabetes Complications. 2021;35(8):107922.
  2. Liu Y, Wang Y, Yang Y, Dong L, Liu Y. Nanoparticle-based insulin delivery systems for diabetes therapy. Curr Pharm Des. 2022;28(5):742–59.
  3. Gupta R, Kumar A, Thakur GS, Verma RK. Smart glucose-responsive nanocarriers for insulin delivery: A review. Int J Biol Macromol. 2021;193:1834–50.
  4. Miao J, Lin S, Zhang T, Zhang W, Yang J. Recent advances in glucose nanosensors for diabetes monitoring. Biosens Bioelectron. 2023;225:115091.
  5. Zhao X, Li Y, Zhao Z, Wang X. Advances in oral insulin delivery systems: Strategies and clinical perspectives. Acta Biomater. 2022;138:1–15.
  6. Patil R, Gaikwad P, Pandit R, Giri AP. Nanotechnology in diabetes management: A comprehensive review. J Drug Target. 2023;31(2):119–36.
  7. Jiang Y, Yu Y, Wang C, Zhang J. Inhalable nanomedicine for pulmonary insulin delivery. Adv Drug Deliv Rev. 2022;182:114147.
  8. Kumar P, Pathak R, Malhotra B, Srivastava S. Nanostructured biosensors for non-invasive glucose monitoring. Sens Actuators B Chem. 2021;341:130043.
  9. Wei Z, Zhang P, Zhu H, Zhu Y. Emerging nanomaterials for smart insulin delivery. J Control Release. 2022;350:405–23.
  10. Tiwari P, Sen P, Singh S, Jain R. Nanomedicine in diabetic complications: Mechanisms and translational challenges. Biomed Pharmacother. 2023;159:114204.
  11. Mahato K, Srivastava A, Chandra P. AI-integrated nanomedicine for diabetes: Current status and future perspectives. Nano Today. 2022;42:101366.
  12. Khursheed R, Jain V, Jain A, Kesharwani P. CRISPR-nanoparticle therapy for diabetes: An emerging approach. Eur J Pharm Biopharm. 2021;167:233–48.
  13. Alavi M, Karimi N. Nanotechnology-driven exosome-based therapeutics for diabetes. J Cell Physiol. 2022;237(4):1956–75.
  14. Singh M, Mehta A. Polymeric nanoparticles for oral insulin delivery: Overcoming gastrointestinal barriers. Pharmaceutics. 2021;13(12):2094.
  15. Xie J, Liu Y, Liu Y. Liposome-based insulin delivery for diabetes treatment: An overview. J Nanobiotechnol. 2023;21(1):45.
  16. Wang L, Li Y, Hou Y, Han J. Injectable nanogels for glucose-responsive insulin release. Carbohydr Polym. 2022;284:119180.
  17. Zhao H, Zhang S, Wu H. Advances in hydrogel-based insulin carriers for controlled release. Int J Pharm. 2023;635:122664.
  18. Bose RJC, Kumar SU, Ghosh G, Chan M, Kohane DS. Stem cell-loaded nanocarriers for pancreatic regeneration in diabetes. Adv Drug Deliv Rev. 2022;184:114244.
  19. Dutta S, Chakraborty S, Ghosh N. Smart microneedles for transdermal insulin delivery. J Mater Chem B. 2021;9(16):3350–62.
  20. Yan H, Wang L, Zhang Y. Lab-on-a-chip technology for point-of-care diabetes diagnosis. Biosens Bioelectron. 2022;216:114684.
  21. Goyal R, Mehta SC. Phytochemical-loaded nanoparticles in diabetes management. Curr Pharm Des. 2021;27(12):1486–99.
  22. Yadav R, Kumar V, Tripathi P. Nanomedicine for diabetic neuropathy and retinopathy. J Control Release. 2023;358:650–71.
  23. Zhang M, Song Y, Wu J. Nanoparticle-based strategies for precision diabetes therapy. Nanoscale. 2022;14(5):1976–93.
  24. Choudhury H, Gorain B, Kundu A. Nanocarriers for GLP-1 analogs in diabetes treatment. Pharmaceutics. 2023;15(4):622.
  25. Desai PR, Rodriguez J, Guo Y. Smart insulin-releasing polymeric nanoparticles. J Biomed Mater Res B Appl Biomater. 2022;110(2):344–56.
  26. Khan S, Jahan R, Ahmad I. Theranostic nanoparticles for diabetes and its complications. Biomed Mater. 2023;18(3):350012.
  27. Guo Z, Li P, Shen X. Nanomedicine in personalized diabetes care. Acta Biomater. 2022;139:219–33.
  28. Patel M, Kumar A, Sharma P. Carbon-based nanomaterials for glucose sensing. Sens Actuators B Chem. 2021;349:130737.
  29. Liu F, Zhao J, Zhang K. Nanofiber scaffolds for pancreatic islet transplantation in diabetes. Biomaterials. 2022;288:121723.
  30. Gao J, Xu L, Zhang T. Injectable nanogels for continuous glucose monitoring. J Mater Chem B. 2023;11(1):134–48.
  31. Kim H, Kim J, Rhee WJ. Gene-editing nanoparticles for diabetes therapy. J Drug Target. 2021;29(6):687–99.
  32. Mittal N, Mahapatra D, Mohapatra S. Regulatory challenges in nano-drug development for diabetes. Eur J Pharm Sci. 2023;191:106365.
  33. Aggarwal P, Thakur S. Nanomedicine in diabetic foot ulcer treatment. Biomed Pharmacother. 2022;146:112654.
  34. McRae MP, Simmons GW, Wong J. Saliva-based nanosensors for glucose detection. Biosens Bioelectron. 2021;197:113767.
  35. Liu Z, Tang S. Nanotechnology-driven precision medicine in diabetes. Adv Drug Deliv Rev. 2022;180:114130.
  36. Gupta R, Sharma M, Tiwari P. Challenges in nano-insulin commercialization. Int J Pharm. 2023;630:122722.
  37. Martinez M, Pena F. Quantum dot biosensors for glucose monitoring. Sens Actuators B Chem. 2022;357:131749.
  38. Zhao Y, Zhang L, Ma X. AI-driven diagnostics and nanomedicine in diabetes. Biomed Signal Process Control. 2021;70:103045.
  39. Huang X, Xue T, Wang Q. Gold nanoparticle-based insulin carriers. J Nanobiotechnol. 2022;20(1):154.
  40. Lin H, Yang X, Zhao Q. Nanoparticle-enabled immunotherapy for diabetes. Nat Rev Endocrinol. 2023;19(2):78–93.
  41. Kang Y, Xu Y. Biodegradable nanoparticles for sustained insulin delivery. Biomater Sci. 2021;9(22):7412–24.
  42. Wu P, Chen Y, Wang Z. Targeted nanoparticle therapy for pancreatic regeneration. Adv Mater. 2023;35(12):e2207689.
  43. Shah S, Raina N. Nanocarrier-mediated antioxidant therapy in diabetes. Pharm Res. 2022;39(7):1685–702.
  44. Kumar S, Saha S, Singh K, Singh T, Mishra AK, Dubey BN, et al. Beneficial effects of spirulina on brain health: A systematic review. Curr Funct Foods. 2024;3(1):e120124225622. https://doi.org/10.2174/0126668629269256231222092721
  45. Ravi K, Kumar VR, Rathi S, Singh S, Patel B, Singh S, et al. A comprehensive review on ulcer and their treatment. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 21;39:e20230006. doi:10.62958/j.cjap.2023.006. PMID: 38755116.
  46. Singh V, Arora S, Akram W, Alam S, Kumari L, Kumar N, et al. Involvement of molecular mechanism and biological activities of Pemirolast: A therapeutic review. New Emirates Med J. 2024;5:e02506882308410. https://doi.org/10.2174/0102506882308410240607053814
  47. Rajput DS, Gupta N, Singh S, Sharma B. A comprehensive review: Personalized medicine for rare disease cancer treatment. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 23;39:e20230008. doi:10.62958/j.cjap.2023.008
  48. Singh S, Chaurasia A, Rajput DS, Gupta N. Mucoadhesive drug delivery system and their future prospective: Are a promising approach for effective treatment? Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 20;39:e20230005. doi:10.62958/j.cjap.2023.005
  49. Kumar S, Saha S, Sharma B, Singh S, Shukla P, Mukherjee S, et al. The role of resveratrol in Alzheimer’s disease: A comprehensive review of current research. Curr Funct Foods. 2023;2(2):e121223224364. https://doi.org/10.2174/0126668629269244231127071411
  50. Patel S, Ismail Y, Singh S, Rathi S, Shakya S, Patil SS, et al. Recent innovations and future perspectives in transferosomes for transdermal drug delivery in therapeutic and pharmacological applications. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Oct 24;40:e20240031. doi:10.62958/j.cjap.2024.031. PMID: 39442957.
  51. Vaghela MC, Rathi S, Shirole RL, Verma J, Shaheen, Panigrahi S, et al. Leveraging AI and machine learning in Six-Sigma documentation for pharmaceutical quality assurance. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jul 18;40:e20240005. doi:10.62958/j.cjap.2024.005. PMID: 39019923.
  52. Patel S, Ismail Y, Singh S, Rathi S, Shakya S, Patil SS, et al. Recent innovations and future perspectives in transferosomes for transdermal drug delivery in therapeutic and pharmacological applications. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Oct 24;40:e20240031. doi:10.62958/j.cjap.2024.031. PMID: 39442957.
  53. Kumar S, Saha S, Pathak D, Singh T, Kumar A, Singh K, et al. Cholesterol absorption inhibition by some nutraceuticals. Recent Adv Food Nutr Agric. 2024;16(1):2–11. https://doi.org/10.2174/012772574X285280240220065812
  54. Singh S, Chaurasia A, Rajput DS, Gupta N. An overview on mucoadhesive buccal drug delivery systems & approaches: A comprehensive review. Afr J Biol Sci. 2024;6(5):522–41. doi:10.33472/AFJBS.6.5.2024.522-541
  55. Kumar S, Singh S, Rajput D, Sharma B, Chaturvedi K, Singh N, et al. Pharmacological approaches and herbal interventions for Alzheimer’s disease. Nat Prod J. 2024;14(8):e220124225945. https://doi.org/10.2174/0122103155275266231123090138
  56. Ravikkumar VR, Patel BD, Rathi S, Parthiban S, Upadhye MC, Shah AM, et al. Formulation and evaluation of drumstick leaves tablet as an immunomodulator. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jun 21;40:e20240004. doi:10.62958/j.cjap.2024.004. PMID: 38902996.
  57. Sharma A, Bara G, Keshamma E, Sharma B, Singh S, Singh SP, et al. Cancer biology and therapeutics: A contemporary review. J Cardiovasc Dis Res. 2023;14(10):1229–47.
  58. Dewangan HK, Singh S, Mishra R, Dubey RK. A review on application of nanoadjuvant as delivery system. Int J Appl Pharm. 2020;12(4):24–33. https://doi.org/10.22159/ijap.2020v12i4.36856
  59. Singh S, Chaurasia A, Gupta N, Rajput DS. Effect of formulation parameters on Enalapril Maleate mucoadhesive buccal tablet using quality by design (QbD) approach. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jun 27;40:e20240003. doi:10.62958/j.cjap.2024.003. PMID: 38925868.
  60. Patel SK, Prathyusha S, Kasturi M, Godse KC, Singh R, Rathi S, et al. Optimizing Irbesartan fast dissolving tablets using natural polysaccharides for enhanced drug delivery and patient compliance. Int Res J Multidiscip Scope. 2025;6(1):1181–90. https://doi.org/10.47857/irjms.2025.v06i01.02542
  61. Soni KS, Desale SS, Bronich TK. Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation. J Control Release. 2016;240:109–26.
  62. Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: The past and the future. Adv Drug Deliv Rev. 2013;65(1):104–20.
  63. Makvandi P, Kirkby M, Zare EN, et al. Engineering biomaterial interfaces for stem cell transplantation. ACS Appl Mater Interfaces. 2021;13(32):37726–48.
  64. Zhang L, Wang W, Wang S. Effect of nanoparticle size on drug delivery and tumor accumulation. Appl Mater Today. 2021;15:100902.
  65. Gupta R, Xie H. Nanoparticles in daily life: Applications, toxicity and regulations. J Environ Pathol Toxicol Oncol. 2018;37(3):209–30.
  66. Chen MC, Sonaje K, Chen KJ, et al. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials. 2011;32(36):9826–38.
  67. Sun Q, Ojha T, Kiessling F, et al. Nanotheranostics: Engineering and assembly of multifunctional nanomaterials for diagnosis and therapy. Adv Drug Deliv Rev. 2016;98:34–57.
  68. Zhao Y, Trewyn BG, Slowing II, et al. Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP. J Am Chem Soc. 2009;131(24):8398–400.
  69. Sharma C, Gupta S, Sharma A, et al. Emerging trends in nano-based antidiabetic therapeutics: A path to novel era of treatment. Mater Adv. 2023;4(3):1234–56.
  70. Makvandi P, Kirkby M, Zare EN, et al. Engineering biomaterial interfaces for stem cell transplantation. ACS Appl Mater Interfaces. 2021;13(32):37726–48.
  71. Zhang L, Wang W, Wang S. Effect of nanoparticle size on drug delivery and tumor accumulation. Appl Mater Today. 2021;15:100902.
  72. Gupta R, Xie H. Nanoparticles in daily life: Applications, toxicity and regulations. J Environ Pathol Toxicol Oncol. 2018;37(3):209–30.
  73. Chen MC, Sonaje K, Chen KJ, et al. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials. 2011;32(36):9826–38.
  74. Sun Q, Ojha T, Kiessling F, et al. Nanotheranostics: Engineering and assembly of multifunctional nanomaterials for diagnosis and therapy. Adv Drug Deliv Rev. 2016;98:34–57.
  75. Sethuram L, Thomas J, Mukherjee A, Chandrasekaran N. A review on contemporary nanomaterial-based therapeutics for the treatment of diabetic foot ulcers (DFUs) with special reference to the Indian scenario. Nanoscale Adv. 2022;4(11):2367–98.
Regular Issue Subscription Review Article
Volume 12
Issue 02
Received 27/03/2025
Accepted 01/04/2025
Published 09/07/2025
Publication Time 104 Days
83


My IP

PlumX Metrics